Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05462587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients With Leukocyte Adhesion Deficiency Type II

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Nov 30, 2024 to Nov 30, 2026
    • Site contact updated
    v6
  2. Primary and study completion dates: Sep 30, 2024 to Nov 30, 2024v5
  3. Lead sponsor: Avalo Therapeutics, Inc. to AUG Therapeutics
    • Primary and study completion dates: Dec 31, 2023 to Sep 30, 2024
    v4
  4. Primary and study completion dates: Dec 31, 2022 to Dec 31, 2023
    • Study title shortened, about 5 words
    v3
  5. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jul 15, 2022 to Jul 28, 2022
    • Site details revised
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The primary objective of this study is to evaluate the efficacy and safety of AVTX-803 compared to withdrawal in patients with Leukocyte Adhesion Deficiency, Type II (LAD II).
Trial Details
NCT Number NCT05462587
Lead Sponsor AUG Therapeutics
Conditions
(from sponsor)		 Leukocyte Adhesion Deficiency
Related terms Leukocyte adhesion deficiency type 1
Enrollment 4 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov